All In Biotech

Drug Trial Radar · NCT00982111

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

A Randomized, Multicenter, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Jan 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 633 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

633

Actual

Start

Nov 2, 2009

Primary completion

Nov 14, 2012

Study completion Dec 23, 2020

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Quintiles, Inc.; Parexel; PPD Development, LP; Medidata Solutions; Laboratory Corporation of America; University of Colorado, Denver; Thermo Fisher Scientific, Inc; Pacific Biomarkers; Intertek; Sysmex Inostics GmbH
First posted
Sep 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and pemetrexed will be more effective in improving participant disease than the standard chemotherapy combination alone.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • PemetrexedDrug

    500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles

  • CisplatinDrug

    75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles

  • NecitumumabBiological

    800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival Time (OS)Time frame: Randomization to Death from Any Cause (Up to 31.6 Months)

Locations

101 sites in 20 countries. Site status is shown where the registry gives one.

  • ImClone Investigational Site

    Nyack, New York

  • ImClone Investigational Site

    Kogarah, New South Wales, Australia

  • ImClone Investigational Site

    Hobart, Tasmania, Australia

  • ImClone Investigational Site

    East Bentleigh, Victoria, Australia

  • ImClone Investigational Site

    Rankweil, Austria

  • ImClone Investigational Site

    Vienna, Austria

  • ImClone Investigational Site

    Vienna, Austria

  • ImClone Investigational Site

    Duffel, Belgium

  • ImClone Investigational Site

    Liège, Belgium

  • ImClone Investigational Site

    Namur, Belgium

  • ImClone Investigational Site

    Barretos - SP, Brazil

  • ImClone Investigational Site

    Brasilia, Distrito Federal, Brazil

  • ImClone Investigational Site

    Goiania - GO, Brazil

  • ImClone Investigational Site

    Ijuí, Brazil

  • ImClone Investigational Site

    Itajaí, Brazil

  • ImClone Investigational Site

    Lajeado, Brazil

  • ImClone Investigational Site

    Porto Alegre/RS, Brazil

  • ImClone Investigational Site

    Ribeirão Preto - SP, Brazil

  • ImClone Investigational Site

    Salvador, Brazil

  • ImClone Investigational Site

    Santo Andre - SP, Brazil

  • ImClone Investigational Site

    São Paulo - SP, Brazil

  • ImClone Investigational Site

    Montreal, Quebec, Canada

  • ImClone Investigational Site

    Pula, Croatia

  • ImClone Investigational Site

    Caen, France

  • ImClone Investigational Site

    Paris, France

  • ImClone Investigational Site

    Berlin, Germany

  • ImClone Investigational Site

    Essen, Germany

  • ImClone Investigational Site

    Frankfurt, Germany

  • ImClone Investigational Site

    Gauting, Germany

  • ImClone Investigational Site

    Großhansdorf, Germany

  • ImClone Investigational Site

    Halle, Germany

  • ImClone Investigational Site

    Hamburg, Germany

  • ImClone Investigational Site

    Heidelberg, Germany

  • ImClone Investigational Site

    Hemer, Germany

  • ImClone Investigational Site

    Hofheim, Germany

  • ImClone Investigational Site

    Karlsruhe, Germany

  • ImClone Investigational Site

    Lostau, Germany

  • ImClone Investigational Site

    Löwenstein, Germany

  • ImClone Investigational Site

    Mainz, Germany

  • ImClone Investigational Site

    München, Germany

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.